<DOC>
	<DOC>NCT02533453</DOC>
	<brief_summary>As current study is conducted to provide additional information regarding safety and efficacy Bydureon, exenatide once weekly for injectable suspension, in the Korean population open label, non-comparative, multi-centre design is used.</brief_summary>
	<brief_title>A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Male or female, 1975 years of age diagnosed with type 2 diabetes mellitus Patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies; Metformin Sulphonylurea Thiazolidinedione Metformin and sulphonylurea Metformin and thiazolidinedione Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following medications: 1. Alpha glucosidase inhibitor or meglitinide within 30 days of screening; 2. Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening; 3. DPP4 inhibitors within 30 days of screening; 4. Regular use (&gt; 14 days) of drugs that directly affect gastrointestinal motility within 3 months of screening; 5. Regular use (&gt; 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of screening; 6. GLP1 receptor agonist except exenatide within 3 months of screening; diagnosed with type 1 diabetes mellitus or diabetic ketoacidosis; type 2 diabetes by betacell dysfunction requiring insulin treatment Has ever used exenatide Pregnant or breast feeding patients Hepatic disease (defined by aspartate or alanine transaminase &gt;3.0 times the upper limit of normal Endstage renal disease or severe renal impairment (creatinine clearance &lt; 30 ml/min)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus, T2DM, GLP-1, GLP-1 Once weekly, Exenatide</keyword>
</DOC>